Introduction
Breast cancer (BC) is the most common malignant tumor among women on a global scale, and its incidence is increasing yearly, with the number of new BC patients reaching 2.26 million worldwide in 2020 [1, 2]. BC, previously believed to exhibit low immunogenicity, has been increasingly recognized for its involvement with the immune system, particularly in the case of triple-negative breast cancer (TNBC) [3, 4]. In recent years, immunotherapeutic drugs represented by immune checkpoint inhibitors (ICIs) have carried out a range of clinical studies in the area of BC treatment and achieved encouraging results. For example, PD-1 or PD-L1 blockers in combination with chemotherapy have been shown to improve the prognosis of patients with TNBC [5‐7]. Tremelimumab, an FDA-approved CTLA-4 blocker for liver cancer and non-small cell lung cancer, has also demonstrated potential benefits through immune activation in BC patients [8‐10]. Moreover, several preclinical trials have demonstrated the positive efficacy of Chimeric antigen receptor T (CAR-T) cell therapy in BC treatment, and multiple ongoing clinical trials are evaluating the use of CAR-T for treating BC [11, 12]. Although immunotherapy shows great promise in BC, it still faces the problems of a limited response rate and tumor resistance [13‐17]. Therefore, it is very important to explore the immune status in BC and further identify key regulatory factors.
The correlation between higher levels of tumor infiltrating lymphocytes (TILs) and improved prognosis in BC has been extensively investigated [18‐21]. Higher levels of TILs have been shown to be associated with reduced recurrence and improved overall survival (OS) [22]. Increased infiltration of CD8 + T, T helper 1(Th1), T follicular helper (Tfh) and natural killer (NK) cells in tumors is generally considered to be associated with better prognosis [23‐25]. In contrast, T helper (Th2) and regulatory T cells (Treg) cells were thought to promote tumor progression and metastasis [26, 27].
Anzeige
Peripheral blood lymphocytes (PBLs) are more accessible, noninvasive, and far less costly than TILs [28]. In addition, several studies indicate that PBLs predicted response to Neoadjuvant therapy (NAT) on some tumors, including prostate cancer, oesophageal cancer, and lung cancer [29‐31]. Nevertheless, our understanding of the diagnostic significance of PBL subsets in assessing the immune status of BC patients remains limited. And it still unclear how chemotherapy causes changes in PBL subsets. Therefore, exploring the landscape of PBLs subsets can enhance our comprehension of the intricate interplay between the immune system and diseases, thus yielding valuable insights for precision medicine [32].
Therefore, this study aims to analyse the baseline status of PBL subsets in BC patients and the changes induced by therapy, as well as the association between PBL subsets and prognosis. Indeed, our analysis suggests that PBL subsets levels at baseline are associated with patient prognosis, especially the levels of CD4 + T and CD19 + CD32 + B cells at baseline. Moreover, there may be a certain regularity in the changes of PBL subsets during chemotherapy, which needs to be further explored.
Methods
Clinical samples and databases
Peripheral blood (PB) samples were collected from a cohort of 74 patients with BC who received treatment at the Second Xiangya Hospital, Central South University in Changsha, China.
Considering the differences in immunogenicity of different breast cancer subtypes and the impact of different chemotherapy regimens on the immune environment [4, 33‐35], patients can be classified as follows: luminal-like (ER or PR positive, or both; HER2 negative, HR + HER2-); HER2 positive (HER2 positive, HER2+); or triple negative (ER negative, PR negative, and HER2 negative, TNBC).
Anzeige
The chemotherapy regimens in this study can be found in Table 1.
Table 1
Chemotherapy regimens
Reginmen | Drug types | Amounts | Treatment courses |
|---|---|---|---|
AC-P/T | Adriamycin | 60 mg/m2 | q3w x 4 |
Cyclophosphamide | 600 mg/m2 | q3w x 4 | |
Paclitaxel | 175 mg/m2 | q3w x 4 | |
Docetaxel | 75 mg/m2 | q3w x 4 | |
EC-P/T | Epirubicin | 100 mg/m2 | q3w x 4 |
Cyclophosphamide | 600 mg/m2 | q3w x 4 | |
Paclitaxel | 175 mg/m2 | q3w x 4 | |
Docetaxel | 75 mg/m2 | q3w x 4 | |
TAC/PAC | Docetaxel | 80 mg/m2 | q3w x 6 |
Paclitaxel | 75 mg/m2 | q3w x 6 | |
Adriamycin | 50 mg/m2 | q3w x 6 | |
Cyclophosphamide | 600 mg/m2 | q3w x 6 | |
TEC/PEC | Docetaxel | 80 mg/m2 | q3w x 6 |
Paclitaxel | 75 mg/m2 | q3w x 6 | |
Epirubicin | 50 mg/m2 | q3w x 6 | |
Cyclophosphamide | 600 mg/m2 | q3w x 6 |
The clinical characteristics of the patients are listed in Table 2. PB samples were collected from 13 patients who underwent NAT and 61 patients who received adjuvant chemotherapy, and blood was withdrawn before every treatment (Fig. 1). The follow-up period for patients was between 5 and 39 months (30.87 ± 7.80), and the follow-up time was April 2023. The primary end point was event-free survival (EFS), disease progression, recurrence, or death was considered an event.
Table 2
Clinical characteristics of 74 BC patients
Variables | Statistics (N = 74) |
|---|---|
Age at diagnosis, years | |
Median | 50(42.25, 54.00) |
≤ 50 | 40(54.05%) |
> 50 | 34(45.95%) |
Histological grade | |
II | 62(83.78%) |
II-III | 1(1.35%) |
III | 6(8.11%) |
X | 5(6.76%) |
BC Molecular Subtypes | |
HR + HER2- | 35(47.30%) |
HER2+ | 26(35.14%) |
TN | 13(17.57%) |
Lymph Node Metastasis | |
Positive | 32(43.24%) |
Negative | 42(56.76%) |
Tumor Size (cm) | |
≤ 2 | 35(47.30%) |
2–5 | 35(47.30%) |
< 5 | 4(5.41%) |
Fig. 1
Sampling process of PB samples from 74 BC patients. The 74 breast cancer patients were divided into NAT group (n = 13) and Adjuvant therapy group (n = 61) according to treatment methods. Peripheral blood of the patients was detected by flow cytometry before treatment or surgery. Abbreviations: AC, adriamycin combined with cyclophosphamide; EC, epirubicin combined with cyclophosphamide; T, docetaxel; P, paclitaxel; H, herceptin; PEC, paclitaxel combined with epirubicin and cyclophosphamide; TEC, docetaxel combined with epirubicin and cyclophosphamide
×
![]()
Flow cytometry analysis of the immune cell population
PBL subset levels were determined by flow cytometry before each treatment cycle. EDTA-anticoagulated fresh whole blood samples were processed within 2 h of collection by erythrocyte lysis for 10 min using lysing solution (BD Biosciences). After red blood cell lysis, cells were washed with PBS and followed by staining with fluorochrome-conjugated antibodies for 20 min at room temperature. The stained cells were suspended and analyzed using flow cytometry.
Gating strategies of representative flow cytometry plots for PBLs is shown in Supplementary Fig. 1. The PBL subsets consisted of 12 items that were selected for detailed phenotypic analysis, as shown in Table 3. PBLs was analyzed using the following antibody combinations: CD3 + T cells (CD45 + CD3+), CD8 + T cells (CD45 + CD3 + CD8+), CD4 + T cells (CD45 + CD3 + CD4+), Treg cells (CD3 + CD4 + CD25+), PD-L1 + T cells (CD3 + CD274+), LAG-3 + T cells (CD3 + CD223+), TIM3 + T cells (CD3 + CD366+), CTLA-4 + T cells (CD3 + CD152+), CD19 + CD32 + B cells (CD19 + CD32+), NK cells (CD3-CD16 + CD56+). Flow cytometry antibodies were obtained from Biolegend, including CD45-PerCP (clone HI30), CD3- FITC (clone HIT3a), CD8-PE (clone SK1), CD4-APC (clone OKT4), CD25-PE (clone BC96), PD-1-PE (clone EH12.2H7), PD-L1-APC (clone 29E.2A3), TIM-3-PE (clone F38-2E2), Lag-3-APC (clone 7H2C65), CTLA-4-APC (clone BNI3), CD19-PE (clone HIB19), CD32-APC (clone FUN-2), CD56-APC (clone 5.1H11) (Supplementary Table 1).
Table 3
Markers, abbreviations and references of PBL subsets
Marker | Abbreviation | Reference (%) | |
|---|---|---|---|
T cells | CD3 | CD3 + T cells | 67.00 ~ 76.00 |
cytotoxic T (Tc) cells | CD3/CD8 | CD8 + T cells | 21.00 ~ 32.00 |
T Helper (Th) cells | CD3/CD4 | CD4 + T cells | 35.00 ~ 46.00 |
Th/Tc cells | CD3/CD8/CD4 | CD4+/CD8 + cells | 1.09 ~ 2.17 |
regulatory T cells | CD3/CD4/CD25 | Treg cells | 7.48 ~ 15.09 |
PD-L1 + T cells | CD3/CD274 | PD-L1 + T cells | 92.35 ~ 98.18 |
PD-1 + T cells | CD3/CD279 | PD-1 + T cells | 15.96 ~ 26.32 |
LAG-3 + T cells | CD3/CD223 | LAG-3 + T cells | 1.21 ~ 3.03 |
TIM3 + T cells | CD3/CD366 | TIM3 + T cells | 0.90 ~ 2.06 |
CTLA-4 + T cells | CD3/CD152 | CTLA-4 + T cells | 11.06 ~ 28.84 |
B cells | CD19/CD32 | CD19 + CD32 + B cells | 10.36 ~ 16.87 |
naturel killer cells | CD3/CD16/CD56 | NK cells | 11.00 ~ 23.00 |
Anzeige
The reference values were established by the Second Xiangya Hospital of Central South University according to the Guidelines for peripheral lymphocyte subsets by flow cytometry issued by the Ministry of Health of the People’s Republic of China.
Flow cytometric analysis was conducted using a FACSCalibur flow cytometer (Becton-Dickinson, BD Biosciences).
Statistical analysis
The data analysis was performed using SPSS (version 26.0), GraphPad Prism (version 8.0) and R Studio (version 2021.09.0 + 351) software. Normality and homogeneity of variance were assessed using the Shapiro-Wilk normality test and Levene’s test, respectively. If the data passed the normality test, parametric statistical tests (Independent Samples t-test, Paired-Samples t-test, and Welch t-test) or one-way ANOVA were performed. If the data did not pass the normality test, nonparametric statistical tests (Mann-Whitney U test and Kruskal-Wallis test) were used. The chi-squared test was employed to determine differences in proportions. Significance level was set at p < 0.05, with *** indicating p < 0.001, ** indicating p < 0.01, and * indicating p < 0.05.
Results
Characteristics of PBL subsets at baseline
To identify the characteristics of systemic immunity in patients with BC at baseline, we evaluated the levels of PBL subsets. The levels of Treg cells and PD-L1 + T cells in PB at baseline were lower than the reference value (Fig. 2A; Table 4). The patients who received adjuvant therapy had lower levels of Treg cells and PD-L1 + T cells than the reference values (Fig. 2B; Table 4). CD3 + T, Treg, and CTLA-4 + T cells were below reference values at baseline in patients on NAT (Fig. 2C; Table 4). We found that patients who received NAT had higher median pretreatment PD-L1 + T cell levels than patients who received adjuvant therapy (p = 0.028) (Fig. 2D).
Anzeige
Fig. 2
Features of PBL subsets before treatment. (A). Box plots of the distribution of baseline PBL subsets in all BC patients; blue text indicates below the reference value. (B-C). Baseline PBL subset characteristics of patients receiving (B) adjuvant therapy and (C) NAT. (D). Relationship between baseline PBL subsets and treatment regimen, Mann–Whitney U test. (E-G). The proportion of baseline PBL subsets in various molecular subtypes in (E) all patients and (F) patients receiving adjuvant therapy, (G) NAT. *P < 0.05, **P < 0.01, ***P < 0.001. Abbreviations: NAT, neoadjuvant therapy; HR + HER2-, hormone receptor-positive/HER2-negative; HER2+, HER2-positive; TN, triple-negative
×
![]()
Table 4
Median lymphocyte subset levels in different BC subtypes
Lymphocyte subsets | Reference (%) | Baseline | ||
ALL | Adjuvant therapy | Neoadjuvant therapy | ||
CD3 + T | 67.00–76.00 | 67.50(61.00,73.50) | 68.00(61.00,74.00) | 61.00*(55.00,71.00) |
CD8 + T | 21.00–32.00 | 29.00(25.25,35.00) | 29.00(25.00,35.00) | 30.00(27.00,35.00) |
CD4 + T | 35.00–46.00 | 39.00(36.00,45.00) | 41.00(36.00,45.00) | 38.00(35.00,39.00) |
CD4+/CD8 + T | 1.09–2.17 | 1.33(1.04,1.78) | 1.32(1.05,1.79) | 1.33(1.01,1.48) |
Treg | 7.48–15.09 | 5.82*(3.93,7.58) | 5.51*(3.88,7.38) | 5.85*(4.72,9.29) |
PD-L1 + T | 92.35–98.18 | 88.41*(82.22,94.58) | 87.21*(81.60,93.77) | 94.14(88.64,96.61) |
PD-1 + T | 15.96–26.32 | 21.81(19.31,29.13) | 21.17(19.00,28.90) | 24.14(21.76,29.96) |
LAG-3 + T | 1.21–3.03 | 2.24(1.77,2.67) | 2.30(1.78,2.67) | 1.92(1.57,2.67) |
TIM3 + T | 0.90–2.06 | 1.05(0.67,1.91) | 1.07(0.66,1.91) | 0.96(0.75,1.81) |
CTLA-4 + T | 11.06–28.84 | 11.95(7.82,17.71) | 12.46(8.28,17.77) | 8.50*(5.62,16.56) |
CD19 + CD32 + B | 10.36–16.87 | 12.64(9.59,15.00) | 12.88(9.53,14.81) | 12.32(10.43,15.74) |
NK | 11.00–23.00 | 18.51(14.35,23.66) | 18.13(13.47,23.83) | 18.70(14.91,22.55) |
Lymphocyte subsets | Reference (%) | Baseline | ||
HR + HER2- | HER2+ | TNBC | ||
CD3 + T | 67.00–76.00 | 69.00(59.00,72.00) | 65.00*(61.00,71.75) | 68.00(62.00,76.00) |
CD8 + T | 21.00–32.00 | 31.00(27.00,36.00) | 28.00(24.25,30.00) | 28.00(27.00,38.00) |
CD4 + T | 35.00–46.00 | 38.00(35.00,45.00) | 41.50(37.25,44.75) | 41.00(36.00,43.00) |
CD4+/CD8 + T | 1.09–2.17 | 1.25(0.96,1.64) | 1.52(1.22,1.84) | 1.48(0.93,1.67) |
Treg | 7.48–15.09 | 4.97*(3.96,6.49) | 5.15*(3.52,7.57) | 6.38*(5.84,7.99) |
PD-L1 + T | 92.35–98.18 | 88.64*(85.04,93.63) | 86.73*(81.38,93.74) | 93.42(88.04,96.96) |
PD-1 + T | 15.96–26.32 | 21.04(19.31,26.89) | 24.01(21.13,29.49) | 22.49(19.00,29.87) |
LAG-3 + T | 1.21–3.03 | 2.10(1.77,2.76) | 2.08(1.79,2.50) | 2.40(1.73,3.23) |
TIM3 + T | 0.90–2.06 | 1.08(0.75,1.88) | 1.08(0.65,1.92) | 0.75*(0.54,1.83) |
CTLA-4 + T | 11.06–28.84 | 12.46(8.25,17.28) | 11.95(7.72,18.07) | 11.77(7.77,16.55) |
CD19 + CD32 + B | 10.36–16.87 | 12.32(10.05,13.81) | 13.55(9.21,16.33) | 12.41(8.80,15.21) |
NK | 11.00–23.00 | 18.40(14.38,24.14) | 18.01(15.24,21.73) | 18.70(10.28,22.36) |
In addition, Treg and PD-L1 + T cell levels at baseline were lower than the reference values in HR + HER2- subtypes. The baseline levels of CD3 + T, Treg, and PD-L1 + T cells were lower than the reference values in HER2 + subtypes. Treg and TIM3 + T cell levels were below the reference values in TN subtypes (Fig. 2E and G; Table 4). However, there were no significant differences among the three molecular subtypes in baseline PBL subsets (Supplementary Fig. 2).
Alteration of PBL subsets in patients with BC after treatment
Considering the effectiveness of treatment on the immune system in cancer patients [36‐38], we explored the variations in PBL subsets before and after treatment. Compared with baseline levels, CD3 + T (p = 6.95e-05), CD4 + T (p = 9.22e-06) and LAG-3 + T (p = 0.016) cell levels were increased, while CD19 + CD32 + B (p = 5.89e-13) cell levels were decreased after treatment (Fig. 3A). After adjuvant therapy, CD3 + T (p = 0.0030), CD8 + T (p = 0.04), CD4 + T (p = 0.00020), LAG-3 + T (p = 0.030) and TIM-3 + T (p = 0.030) cell levels increased, whereas CD19 + CD32 + B (p = 1.99e-10) cell levels decreased (Fig. 3B). The levels of CD3 + T (p = 0.0041) and CD4 + T (p = 0.030) cells were significantly increased, while those of CD19 + CD32 + B (p = 0.0021) cells were significantly decreased after NAT (Fig. 3C).
Anzeige
Fig. 3
Variations in PBL subsets during systemic therapy. (A-C). PBL subsets before and after treatment were available for (A) all BC patients and patients receiving (B) adjuvant therapy and (C) NAT. (D-E). PBL subsets before and after adjuvant therapy were available for (D) HR + HER2-, (E) HER2 + and (F) TN. Paired T test. *P < 0.05, **P < 0.01, ***P < 0.001. Abbreviations: NAT, neoadjuvant therapy; HR + HER2-, hormone receptor-positive/HER2-negative; HER2+, HER2-positive; TN, triple-negative
×
![]()
Given the small number of patients receiving NAT, we focused the subtype analysis on patients who received adjuvant therapy. In the HR + HER2- subtype, CD3 + T (p = 0.010), CD4 + T (p = 0.0010) and CD4+/CD8 + T (p = 0.042) cells increased and CD19 + CD32 + B (p = 1.03e-05) cells decreased significantly after treatment (Fig. 3D). In HER2 + patients, CD8 + T (p = 8.84e-05) cells increased after treatment and CD4+/CD8 + T (p = 0.0094) cells and CD19 + CD32 + B cells (p = 0.0002) decreased after treatment (Fig. 3E). Among the TN subtypes, only CD19 + CD32 + B (p = 0.038) cells showed a significant decrease (Fig. 3F).
These results suggest that treatment leads to changes in the composition of PBL subsets in BC patients. The changes may be related to the molecular subtype.
Changes in PBL subsets caused by chemotherapeutic drugs
To further explore the specific reasons for the changes in PBL subsets caused by chemotherapy, we analysed the PBL subsets of patients before chemotherapy in each cycle. Interestingly, treatment with different chemotherapy regimens also contributed to the distinct lymphocyte variations. In patients treated with the AC/EC-T/P course, the levels of CD4 + T cells were time dependent, while PEC/TEC did not. Additionally, they increased during the first four cycles of AC/EC-T/P but decreased with the addition of paclitaxel drugs. The levels of CD19 + CD32 + B declined with chemotherapy cycles, regardless of the type of chemotherapeutic drugs (Fig. 4A, B). These findings indicate that paclitaxel seemingly has an inhibitory effect on CD4 + T cells. In patients with different molecular subtypes of BC who received adjuvant therapy, the trends of changes in both CD4 + T and CD19 + CD32 + B cells were basically the same (Fig. 4C, D). Altogether, our results suggest that the changes in CD4 + T cells induced by chemotherapy may be related to the types of drugs.
Fig. 4
PBL subsets are vulnerable to chemotherapeutic drugs. (A). Changes in PBL subsets in patients treated with the AC/EC-T/P regimen. (B). Changes in PBL subsets in patients treated with the PEC/TEC regimen. (C-D). Changes in (C) CD4 + T and (D) CD19 + CD32 + B in different BC molecular subtypes during adjuvant therapy chemotherapy cycles. Abbreviations: HR + HER2-, hormone receptor-positive/HER2-negative; HER2+, HER2-positive; TN, triple-negative; AC, adriamycin combined with cyclophosphamide; EC, epirubicin combined with cyclophosphamide; T, docetaxel; P, paclitaxel; H, herceptin; PEC, paclitaxel combined with epirubicin and cyclophosphamide; TEC, docetaxel combined with epirubicin and cyclophosphamide
×
![]()
Prognostic value of baseline PBL subsets in BC
We investigated the clinical significance of peripheral blood cell subsets at baseline in patients with BC. In univariate Cox regression analysis, CD4 + T cells (HR 0.92, 95% CI 0.852–0.993, p = 0.033) were found to be an important predictor of prognosis (Fig. 5A). The variables with p-values ≤ 0.10 from univariate Cox regression analysis were included in the multivariate Cox regression model, which incorporated CD4 + T cells, CTLA-4 + T cells, and CD19 + CD32 + B cells.
Fig. 5
The clinical significance of the baseline PBL subsets. (A) Forest plot of independent predictors of prognosis in BC patients, univariate Cox regression analysis. (B) Forest plot of independent predictors of prognosis in BC patients, multivariate Cox regression analysis. (C) Nomogram to evaluate model performance. (D) Calibration curve to evaluate model performance. (E) KM EFS curve of CD4 + T cells in BC patients
×
![]()
The results indicate that CD4 + T cells (HR 0.885, 95% CI 0.804–0.975, p = 0.014) and CD19 + CD32 + B cells (HR 1.195, 95% CI 1.028–1.389, p = 0.02) independently predict prognosis (Fig. 5B). A risk formula was developed based on the results of multivariate Cox regression analysis. The risk score was calculated as follows: levels of CD4 + T cells*(-0.12177) + levels of CD19 + CD32 + B cells*(0.1785). The prognostic nomogram and calibration curve demonstrate the model’s high efficacy (Fig. 5C, D).
The patients were divided into two groups based on their PBL expression level, using a cut-off point of 42.00 for CD4 + T cells. The results suggested that patients with a higher baseline level of CD4 + T cells exhibited improved prognosis (p = 0.0051) (Fig. 5E). In summary, our results demonstrate model’s strong predictive ability for prognosis, with PB CD4 + T cells serving as an independent prognostic factor for BC patients.
Discussion
BC is a prominent cause of death among women globally and presents difficulties in achieving successful patient treatment [1]. Increasing evidence indicates that the immune profiles of the host may influence patient outcomes in BC [21, 39, 40]. The immune system is involved in normal breast development and has led to extensive research on the immune landscape of BC patients. Multiple studies have demonstrated that increasing immunogenicity and T-cell infiltration in the PB are potential strategies for the success of BC treatment [31, 41‐43].
Multiple studies have demonstrated the significant role of PBLs in the clinical cure of cancer, especially in the therapeutic response to chemotherapy and improving the survival time in BC patients. Feng et al. expounded that peripheral baseline CD3 + T cells, CD8 + T cells, and NK cells independently predicted pathological complete response (pCR) in BC patients receiving NAT [31]. Li et al. proposed that peripheral CD4 + cells possess a stable ability to predict all clinical outcomes in patients with metastatic triple-negative breast cancer (mTNBC). Furthermore, their study highlighted a significant correlation between this clinical prognosis prediction and chemotherapy [42]. Therefore, this new knowledge may in turn open up opportunities for the stratification and prognosis prediction of BC patients by the quantitative evaluation of PBLs. Upon T-cell receptor (TCR) activation and cytokine stimulation, CD4 + T cells have the capacity to differentiate into various T-helper (Th) cell lineages. These lineages play a crucial role in immune response by releasing specific cytokines in response to different pathogenic insults [44, 45]. CD4 + Th1 cells secrete type I cytokines, specifically interferon-gamma (IFN-γ), leading to the activation of antigen-presenting cells. This activation subsequently stimulates a CD8 + T cell response. On the other hand, CD4 + Th2 cells secrete type II cytokines, including IL-4, IL-5, and IL-13, which contribute to the enhancement of humoral immune responses [46]. It is generally considered that Th1highTh2low is a good indicator of antitumour activity [46]. In our study, we observed a significant alteration in the proportion of CD4 + T cells in PB after chemotherapy. Thus, it is very important to further study the function of CD4 + T cells in BC patients.
Previously, chemotherapy was believed to exert solely immunosuppressive effects. However, recent studies have displayed different immunogenicity patterns in cancer patients undergoing chemotherapy. These patterns arise due to the cytotoxic effects of chemotherapy, which facilitate immunogenic cell death and consequently lead to the release of antigens and danger signals. Such released components contribute to the recruitment of antigen-presenting cells, promote the engulfment of dying cells, and facilitate dendritic cell (DC) maturation. These processes are vital for T-cell priming [33, 47]. Together, these signals stimulate and activate the immune system for antigen recognition and tumor cell elimination by recruiting and activating immune cells [48]. Several kinds of chemotherapy drugs, including anthracyclines, cyclophosphamide, and microtubule-stabilizing agents, are often used in BC. In our study, we found that different chemotherapy drugs may induce different responses to peripheral immunity. The cause of this phenomenon is unclear, but probably related to the mechanism of action of chemotherapy drugs.
In this study, we further established a nomogram containing PBLs to predict patient survival. Within lymphocyte subsets, higher baseline CD4 + and lower baseline CD19 + CD32 + B in PB correlated slightly with a better recurrence-free survival (RFS) in a multivariate Cox model. Previous studies on PBLs were limited to one subtype of breast cancer. A study involving 157 TNBC patients with MBC revealed that decreased pretreatment CD4 + cells in PB were strongly associated with a poorer prognosis [49]. Studies conducted by Jian Yang et al. and Xiao-Ran Liu et al. indicated that plasma CD4 + and peripheral cytotoxic T lymphocytes (pCTLs) were identified as independent negative predictors of progression-free survival (PFS) in HER2 + patients [50, 51]. However, there is no clear biological explanation as to why the same PBL subgroups may have inconsistent prognostic value in different BC subtypes. In our predictive model, we accounted for breast cancer subtypes as a variable to avoid the problem caused by tumor heterogeneity. The performance of a nomogram must be evaluated through calibration and discrimination. Internal validation in this study demonstrated strong discriminatory power (C-index: 0.852) with the inclusion of PBLs in the nomogram. Our nomogram was well calibrated to predict RFS. Therefore, our study can provide noninvasive, accurate and easily accessible predictors for survival in BC patients and assist clinicians in gaining a better understanding of tumor immunity. There are some limitations in this study. First, this is a retrospective study, and the follow-up time of patients involved in this research was short. The results should be further confirmed by prospective studies, and we will continue the follow-up in the long term. Second, the specific type of PBL subsets needs to be explored in depth.
Conclusions
In summary, our results suggest that PBL subsets are helpful in elucidating the systemic immune response of BC. Additionally, the nomogram that incorporates PBLs demonstrated accurate predictions of individualized survival probabilities for BC patients. This practical model has the potential to provide support to clinicians and patients when making clinical decisions and optimizing treatment strategies.
Acknowledgements
We are indebted to all the authors and our colleagues for the fruitful suggestions and discussions.
Declarations
Ethics approval and consent to participate
The study was reviewed and approved by the Research Ethics Committee of the Second Xiangya Hospital of Central South University (No. 2021 [443]) and was conducted in accordance with the ethical guidelines of the Declaration of Helsinki. All patients signed informed consent forms.
Consent for publication
Not applicable.
Competing interests
The authors declare no competing interests.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.